ESC Premium Access

Longterm comparative efficacy of drug-eluting stents versus bare metal stents in saphenous vein graft lesions: 5-year clinical follow-up of a randomized trial

Congress Session

About the speaker

Doctor Roisin Colleran

Mater Private Network Dublin, Dublin (Ireland)
2 presentations
0 follower

8 more presentations in this session

Impact of neoatherosclerosis in lesions with in-stent restenosis evaluated by optical coherence tomography on mid-term outcome after plain old balloon angioplasty and drug coated balloon

Speaker: Doctor D. Nakamura (Osaka, JP)

Thumbnail

Temporal trends in PCI outcomes in the elderly: An analysis from the British Columbia Cardiac Registry

Speaker: Doctor H. Contractor (Manchester, GB)

Thumbnail

Comparison of late catch-up phenomenon after second generation DES implantation with bare metal stent implantation assessed by optical coherence tomography

Speaker: Doctor T. Kajiya (Kagoshima, JP)

Thumbnail

Outcomes of patients with coronary CTOs up to 15 years follow-up: insights from the CLOSE study (coronary chronic total occlusions long term outcomes after successful percutaneous revascularization)

Speaker: Doctor F. Melillo (Milan, IT)

Thumbnail

The impact of renal disease on target vessel revascularisation following percutaneous coronary intervention: a contemporary analysis of 45,287 patients from the British Columbia Cardiac Registry.

Speaker: Doctor N. Chandra (Wexham Park Hospital, GB)

Thumbnail

Access the full session

Targeting very late restenosis

Speakers: Doctor R. Colleran, Doctor D. Nakamura, Doctor H. Contractor, Doctor T. Kajiya, Doctor F. Melillo...
Thumbnail

About the event

Image

ESC CONGRESS 2017

26 August - 30 August 2017

Sessions Presentations

Related content

ESC Premium Access

Diagnosis of CCS: from the clinical likelihood to the assessment of event risk.

29 August 2021

ESC Premium Access

MASTER DAPT - Discussant review.

28 August 2021

ESC Premium Access

MASTER DAPT: dual antiplatelet therapy after coronary stenting in high bleeding risk patients

28 August 2021

This platform is supported by

logo Novo Nordisk